US Patent

US11338007 — Combination formulation of three antiviral compounds

Method of Use · Assigned to Gilead Sciences Inc · Expires 2037-06-01 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions containing velpatasvir, sofosbuvir, and voxilaprevir, as well as methods of using these compositions.

USPTO Abstract

Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2039`	—

Patent Metadata

Patent number: US11338007
Jurisdiction: US
Classification: Method of Use
Expires: 2037-06-01
Drug substance claim: No
Drug product claim: Yes
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.